Ultragenyx Pharmaceutical (RARE) EBT (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly EBT of -$184.0 million for Q1 2026, down 22.67% year-over-year from -$237.9 million in Q1 2025, and down 51.21% quarter-over-quarter from -$121.7 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) EBT (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported EBT for 14 consecutive years, with -$184.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBT fell 22.67% year-over-year to -$184.0 million; the TTM figure through Mar 2026 stood at -$599.2 million (down 10.4% YoY), while the FY2025 annual figure was -$565.0 million, changed 0.36% from the prior year.
- EBT retreated to -$184.0 million in Q1 2026 per RARE's latest filing, from -$121.7 million in the prior quarter.
- Across five years, EBT topped out at -$114.0 million in Q2 2025 and bottomed at -$238.8 million in Q3 2022.
- Historically, EBT has averaged -$154.3 million across 5 years, with a median of -$153.3 million in 2022.
- Annual changes were most pronounced in 2022 — EBT tumbled 227.98% — and 2023, when it jumped 33.42%.
- Ultragenyx Pharmaceutical's EBT stood at -$153.3 million in 2022, then gained by 16.87% to -$127.4 million in 2023, then decreased by 1.09% to -$128.8 million in 2024, then rose by 5.54% to -$121.7 million in 2025, then tumbled by 51.21% to -$184.0 million in 2026.
- Business Quant data shows RARE's EBT at -$184.0 million in Q1 2026, -$121.7 million in Q4 2025, and -$179.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -91.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -91.00 Mn |
| Mar 31, 2026 | -184.00 Mn |
| Dec 31, 2025 | -121.69 Mn |
| Sep 30, 2025 | -179.54 Mn |
| Jun 30, 2025 | -114.00 Mn |
| Mar 31, 2025 | -150.00 Mn |
| Dec 31, 2024 | -128.82 Mn |
| Sep 30, 2024 | -133.21 Mn |
| Jun 30, 2024 | -130.74 Mn |
| Mar 31, 2024 | -170.23 Mn |
| Dec 31, 2023 | -127.43 Mn |
| Sep 30, 2023 | -159.00 Mn |
| Jun 30, 2023 | -159.10 Mn |
| Mar 31, 2023 | -163.48 Mn |
| Dec 31, 2022 | -153.28 Mn |
| Sep 30, 2022 | -238.82 Mn |
| Jun 30, 2022 | -157.86 Mn |
| Mar 31, 2022 | -151.76 Mn |
| Dec 31, 2021 | 332.88 Mn |
| Sep 30, 2021 | -72.82 Mn |